Bone & Mineral SIG

Skeletal Physiology, Weight Wellness, and Optimizing The Musculoskeletal Healthspan (with Obesity SIG)

Date: April 21, 2026
Moderators:

Jami Josefson, MD, MS
Associate Professor of Pediatrics - Endocrinology
Feinberg School of Medicine
Northwestern University

M. Furkan Burak, MD
Assistant Professor of Medicine
Mass General Brigham 
Harvard Medical School

Dwight A. Towler, MD, PhD
Professor of Medicine - Diabetes Endocrinology and Metabolism
Vanderbilt University Medical Center
Vanderbilt Health

Speakers: 

Clifford J. Rosen, MD
Professor and Director, Tufts Clinical and Translational Science Institute
Maine Medical Center Research Institute
Tufts University School of Medicine
Topic: GLP1  Endocrine Pharmacology,  Marrow Physiology and Skeletal Health

Sowmya Krishnan, MD
Professor of Pediatrics - Endocrinology
Children’s Medical Center of Dallas
UT Southwestern Medical Center
Topic: Obesity Management in Adolescents and Young Adults: Strategies and Unmet Needs Relevant To Optimizing the Skeletal Healthspan

Elaine Yu, MD, MMSC
Associate Professor of Medicine - Endocrinology
Mass General Brigham / HSM
Harvard University
Topic: Balancing Weight Wellness and Musculoskeletal Fraily in Aging Patients using GLP1/GIP Agonists

Description: 

This is a collaborative webinar on obesity management, weight wellness, and musculoskeletal health. In the era of GLP1 agonist - based therapies used to successfully achieve weight wellness, a better understanding of these impact skeletal physiology across the healthspan is needed. The complex pharmacology of GLP1/GIP agents on marrow cell fate and phenotype as relevant to skeletal physiology and obesity medicine is presented by Dr. Rosen. The gaps and needs in pediatric/adolescent weight wellness as relates to young adult bone health will be addressed by Dr. Krishnan. Dr. Yu will reflect upon the integrated goals of care for T2D, obesity and weight wellness management vis-a-vis musculoskeletal frailty risk in our aging population. After the 3 individual presentations, there would be a ca. 30 minute online panel discussion of the unmet scientific/clinical needs and future directions – with a post-webinar strategy discussion for getting this topic on the ENDO 2027 schedule as a symposium.

Learning Objectives: 

1. Described the impact of GLP1 receptor agonists on marrow mesenchymal cell lineage allocation and osteoblast-osteoclast interactions determine bone mass and strength
2. Understand the role of achieving peak bone mass in young adulthood on skeletal strength across the lifespan, and impacts of well wellness management on bone mass accrual in the maturing skeleton.
3. Describe the integrated goals of care for managing T2D, obesity and weight wellness while mitigating musculoskeletal frailty and fracture risk in our aging patients.

Bone Health During the Perimenopausal Transition

Date: December 2, 2025
Moderators:

• Susan Tibuni-Sanders, MD, Kaiser Permanente, San Francisco, Chair of Women's Health SIG
• Muriel Babey, MD, Assistant Professor of Medicine, Adjunct, University of California, San Francisco, Co-Chair of Bone and Mineral SIG

Speakers:

• Maria Schuller Almeida, PhD, Professor, Departments of Internal Medicine and Orthopedic Surgery, Associate Director, Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences
• Amanda L Clark, MD, MCR, MSCP, Professor Emeritam, Urogynecology and Reconstructive Pelvic Surgery, Obstetrics and Gynecology, Oregon Health & Science University
• Mark Bolland, MD, Associate Professor, Faculty of Medical and Health Sciences, Medicine, University of Auckland, New Zealand

Description:

This webinar will examine bone health during the perimenopausal transition, a critical window of accelerated bone loss and skeletal adaptation. Presentations will review the hormonal and cellular mechanisms underlying perimenopausal bone loss, clinical approaches to assessment and prevention, and recent evidence from trials evaluating zoledronic acid for bone preservation.

Each presentation will last approximately 25 minutes, followed by a 5-minute question-and-answer session.

Learning Objectives:

Upon completion of this activity, participants will be able to:

1. Examine the basic and translational mechanisms driving bone loss during the perimenopausal transition.
2. Discuss clinical strategies for assessing, monitoring, and maintaining bone health during this period.
3. Understand the design and outcomes of the 5-yearly zoledronic acid trial and its implications for bone preservation.

Access Recording

Vitamin D – Contemporary Data and Controversies

Date: Tuesday, April 8, 2025
Time: 11:30 AM–1:00 PM ET

Moderator:

• Nicola Napoli, MD, PhD, University Campus Bio-Medico di Roma 
• Dolores Shoback, MD, University of California – San Francisco

Speakers: 

• Marie Demay, MD, Professor of Medicine, Harvard Medical School
• Anastassios Pittas, MD, Chief, Endocrinology, Diabetes and Metabolism; Co-Director, Diabetes and Lipid Center; Professor, Tufts University School of Medicine
• Carlos Bernal-Mizrachi, MD, Chief of Medicine, Veterans Affairs St. Louis Health Care System; Professor of Medicine, Washington University St Louis

Description: 

In this webinar leading experts will discuss the latest research, controversies, and clinical implications of vitamin D supplementation. Join us for the following presentations:

• Dr. Marie Demay - "Making Sense of the Endocrine Society Vitamin D for the Prevention of Disease Guidelines"
• Dr. Anastassios Pittas - “Vitamin D in People with Prediabetes”
• Dr. Carlos Bernal-Mizrachi - “Pregnant Vitamin D Deficiency and the Epigenetic Programming of Immune Cells to Cause Insulin Resistance”

Each talk will last approximately 25 minutes, with 5 minutes for a question-and-answer session.

Learning Objectives:

• Objective 1: To summarize key findings from evidence-based literature analyses of the effects of vitamin D on disease prevention in a healthy population 
• Objective 2: To evaluate the evidence on vitamin D for diabetes prevention in individuals with prediabetes, examining its potential role, clinical implications, and remaining controversies
• Objective 3: To summarize the impact of in utero vitamin D deficiency on the epigenetic programming of hematopoietic stem cells (HSCs) and its subsequent effect on inducing insulin resistance (IR) and type 2 diabetes mellitus in offspring in humans and mice. 

Date: March 26, 2024 

Moderator:
Joy Y. Wu, MD, PhD, Stanford University School of Medicine

Speakers:
Patricia Juarez Camacho, PhD, CICESE, Mexico: “Bone Health and Metastatic Breast Cancer”
Serkin Park, DDS, MS, PhD, Korea University, Korea: "The Roles of Osteoblasts in Breast Cancer Bone Metastasis"
Azeez Farooki, MD, Memorial Sloan Kettering Cancer Center, United States: “Adjuvant and Antifracture Effects of Antiresorptives in Postmenopausal Breast Cancer”

Description:
In this webinar, we will be able to understand the basic science of breast cancer and bone health, including breast bone metastasis mechanisms. Additionally, we will grasp the role of osteoblasts in the bone metastatic microenvironment and recognize their diagnostic potential. Lastly, we will discuss the adjuvant and antifracture effects of antiresorptives in postmenopausal breast cancer.

The presentation will be split into three sections focusing on basic science, translational science, and clinical practice. Each talk will last approximately 25 minutes, with 5 minutes for a question-and-answer session.

Learning Objectives:

• Examine the basic science aspect of breast cancer and bone health, including mechanisms of breast bone metastasis.
• Understand the role of osteoblasts in the metastatic bone microenvironment and recognize their diagnostic potential.
• Discuss adjuvant and anti-fracture effects of antiresorptives in postmenopausal breast cancer.

Date: Tuesday, December 3, 2024
Time: 11:30 AM–1:00 PM ET

Moderator: Nicola C. Partridge, PhD, Rutgers University

Speakers:

• Jean-Pierre Viladarga, PhD, University of Pittsburgh School of Medicine – “The Druggability of the PTH/PTHrP Receptor”
• Jakob Hoeppner, MD, Massachusetts General Hospital and Harvard Medical School – “Novel Insights into PTH/PTHrP Receptor Signaling Regulation from Eiken Syndrome”
• Alison Boyce, MD, National Institute of Dental and Craniofacial Research – “Treatment Strategies for Fibrous Dysplasia / McCune-Albright Syndrome”

Description: 

In this webinar, we will understand the basic science of PTH/PTHrP receptor signaling and how to discover small non-peptidic molecules that might act through this receptor. Additionally, we will discuss Fibrous Dysplasia / McCune-Albright Syndrome (FD/MAS) and possible treatments and results of clinical trials. This lineup is intended to foster a logical progression from receptor targeting to disease model insights and clinical application. It is designed to engage both basic scientists and clinicians, fostering discussion on the latest research and therapeutic approaches in this field.

Each talk will last approximately 25 minutes, with 5 minutes for a question-and-answer session. 

Learning Objectives:

1. Examine the basic science investigation of small allosteric molecules that modulate PTH/PTHrP receptor signaling. 
2. Understand how PTHR1 signaling is fine-tuned by β-arrestins, responsible for specific biological functions of this receptor. 
3. Discuss FD/MAS and emerging treatments, including results of clinical trials.